A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer-Reference-Cited by-同舟云学术

A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer

Published:2018-10-01 Issue:7 Volume:37 Page:1297-1303
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Pozo Carmen^ORCID,Hernández Virginia,Capitán Carlos,de la Peña Enrique,Fernández-Conejo Guillermo,Martínez María del Mar,del Riego Silvia,Pérez-Fernández Elia,Llorente Carlos

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00345-018-2500-7.pdf

Reference31 articles.

1. North American Association of Central Cancer Registries (NAACCR) 2016

2. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V et al (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981–990

3. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C et al (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100:1144–1154

4. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB et al (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65:1046–1055

5. Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M et al (2011) Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 12:891–899

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS‐JAPAN study;International Journal of Urology;2022-07-19

2. Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil;Value in Health Regional Issues;2021-12

3. Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance;European Urology Open Science;2021-01